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ABSTRACT
Introduction: Topical delivery of eye drops which currently accounts to 90% of available 
ocular dosage forms are ideal for the treatment of eye diseases but having limitations 
of poor therapeutic response and low bioavailability. Objectives: The objectives 
of present research was to develop and characterize sustained release in situ ocular 
gels containing sufacetamide sodium using pH induced gelling polymers for improved 
therapeutic response and patient compliance. Methods: In situ gel formulations prepared 
by dispersion method using Carbopol® 940/Carbopol® 934 alone or in combination 
with hydroxypropyl methylcellulose (HPMC E4M). Formultaions were evaluated for 
appearance, pH, viscosity, gelling capacity, drug content and in vitro drug release. The 
optimized formulation was assessed for sterility and antimicrobial efficacy using disk 
diffusion technique in comparison to commercial eye drops (Albucid®10%). Results: The 
appearance of in situ gels were clear and free flowing in nature however, a viscous 
clear solution with no flow was produced for formulations consisting of 0.8% w/v 
Carbopol® 940/Carbopol® 934 and 2% w/v HPMC E4M. pH of all the formulations was 
within the range of 5.9 to 6.7. In situ gels with Carbopol® 940 demonstrated higher 
viscosity compared to Carbopol® 934 and drug release was sustained over a period of 8 
hr. The selected formulation containing 0.8% w/v Carbopol® 940 and 1.5% w/v HPMC 
E4M passed sterility test and demonstrated similar antimicrobial efficiency compared to 
commercial product. Conclusion: Carbopol®/HPMC-based in situ gels have potential to 
improve patient’s compliance by reducing the dosing frequency and could be a viable 
alternative to commercial product.
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Ocular drug delivery is one of  the most 
interesting and challenging areas of  phar-
maceutical research. Topical delivery of  eye 
drops which currently accounts for 90% of  
accessible ocular formulations is an ideal 
treatment for ocular diseases especially 




ized action. However, topical delivery is 
not without problems such as the poor bio-
availability and therapeutic response. These 
challenges are attributable to the rapid pre-
corneal elimination due to tear secretion, 
non-productive absorption due to the bio-
logical barrier for drug penetration, absorp-
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tion into the gastrointestinal tract due to drainage through 
nasal lacrimal duct and poor patient’s compliance due 
to increasing number of  instillations and difficulty in 
self-administration.1-4 Thus, the concept of  polymeric 
in situ gel forming system was introduced to alleviate 
these problems. In situ gels are free flowing solutions 
at room temperature that undergo phase transition 
from solution-gel (sol-gel) as a result of  exposure to 
physiological temperature, pH or ionic compositions of  
lacrimal fluid.5-7 The gel formed in the eye effectively 
prevents the rapid drainage of  instilled drug from ocular 
site, improves the retention time of  dosage form at the 
site of  administration and sustains the drug release for 
a prolonged period of  time. It aids to reduce the dosing 
frequency and to improve the therapeutic efficiency of  
drug. Furthermore, systemic side effects would also be 
reduced due to less systemic absorption. Therefore, it 
enhances patient’s compliance and convienence.5
Carbopol® is a water soluble pH dependent in situ 
polymer. The formulations comprising of  Carbopol® 
polymer remained as solution at acidic pH and forms 
a low viscosity gel when pH raised to alkaline. The pH 
difference between the formulations containing 
Carbopol® and human tear fluid makes the sol-gel 
transition occurs almost instantly. Besides, Carbopol® 
has an excellent mucoadhesive property. Therefore, the 
polymer is responsible to increase the contact time of  
a drug in the eye by adhering to the ocular surface and 
thereby release the drug in a controlled fashion. However, 
acidic nature of  Carbopol® may cause damage to surface 
of  eye before being neutralized by the lacrimal fluid. 
Thus, HPMC, a viscosity enhancing polymer is usually 
added to Carbopol® contained formulations to overcome 
this problem, which resulted in pH induced polymeric 
mixture (Carbopol®/HPMC). This polymeric mixture is 
in liquid state at it’s native formulated pH 4 to 6 at room 
temperature but rapid transition into gel phase occurs 
at the pH of  tear fluid (pH 7.4).3,8-10 To date, many of  
the ocular in situ forming gels have been investigated 
with a combination of  Carbopol® and cellulose deriva-
tives.8,11-13 In addition, these two polymers are already 
listed in the FDA’s Inactive Ingredient Guide (IIG) and 
widely used commercially for various drug applications 
including topical ophthalmic solutions.14-16 Therefore, 
these polymers are considered to be safe to use. 
Sulfacetamide sodium is a sulfonamide with antibacterial 
activity. It is commerically available in the dosage forms 
of  lotion and solution. The ocular dosage form is 
commonly used to treat conjunctivitis and other superficial 
ocular infections caused by susceptible micro-organisms 
such as Staphylococcus aureus, Escherichia coli, 
Streptococcus pneumoniae, Klebsiella species and 
Enterobacter species. The major drawback of  commercial 
eye drops, however, is the dosing frequency, which has 
to be administered 1 to 2 drops every 2 to 3 hr (8 to 
12 times in a day).17 This high frequency of  sulfacetamide 
sodium eye drops administration is associated with poor 
patient compliance and convenience. To overcome all 
the aforementioned constrains offered by eye drops, 
an alternative apporach of  in situ gelling system with a 
combination of  Carbopol® and HPMC was investigated 
as a vehicle for the formulation of  sustained release 
smart eye drops containing sulfacetamide sodium. 
Furthermore, to the best of  our knowledge, till date 
there is no published literature on the formulation of  
in situ gels containing sulfacetamide sodium. 
MATERIALS AND METHODS
Materials
Sulfacetamide sodium, methyl paraben and propyl paraben 
were purchased from Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA). Carbopol® polymers (Carbopol® 
940 and Carbopol® 934) were purchased from DCM 
personal care Sdn Bhd (Selangor, Malaysia). HPMC 
E4M was obtained as a gift sample from Dow Chemical 
Co. (Illinois, USA). Muller Hinton agar medium and 
fluid thioglycolate medium were purchased from Becton 
Dickinson Sdn Bhd (Selangor, Malaysia). All other 
solvents and chemicals used were of  analytical grade.
Preparation of in situ gel formulations
The composition of  in situ gel formulations containing 
sulfacetamide sodium is shown in Table 1. In situ gel 
formulations containing different concentratios of  
Carbopol® 940/Carbopol® 934 in combination with 
HPMC E4M were prepared by dispersion method.18-20 
Briefly, about 75 mL distilled water was preheated to 
70°C to dissolve methyl and propylparaben and then 
sodium chloride (NaCl), HPMC and Carbopol® were 
incorporated into the solution. The mixture was left 
at room tempeature overnight to allow the polymer to 
hydrate. Sulfacetamide sodium was dissolved in 25mL 
distilled water separately. It was added into above 
polymeric solution and stirred until a uniform solution 
was obtained. The final product was filled into sterile 
amber colour bottles and sterilized in autoclave at 121°C 
for 15 min. The prepared formulations were stored in 
refrigerator at 4°C until further use.
Evaluation of in situ gel formulations
Appearance and clarity, pH and drug content
The appearance and clarity of  formulations were 
observed visually against a black and white background for 
presence of  any particulate matter in the formulation.4 
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The pH of  formulations was determined using a digital 
pH meter (METTLER Toledo, S220 SevenCompact™ 
pH/Ion) to ensure that the formulations do not cause 
any ocular irritation to the patient upon administration. 
To determine the drug content in the formulations, 
1 mL of  the formulation was dissolved in 100 mL 
simulated tear fluid (STF, pH 7.4) and further diluted 
with same medium to measure the absorbance using 
UV-Visible spectrophotometer at a wavelength of  257 nm. 
The composition of  STF pH 7.4 is as follows: 0.670 g 
of  NaCl, 0.200 g of  NaHCO3, 0.008 g of  CaCl2. 2H2O 
and distilled water up to 100 mL. The samples were 
measured in triplicate.
Viscosity
The viscosity of  the formulations was determined using 
DV-III ULTRA Programmable Rheometer (Model LV) 
using a spindle-SC4-18 which is immersed in a formula-
tion to be tested. The spindle speed was set at 20 rpm 
and and the temperature was maintained at 25°C. 
The viscosity values were calculated using Bingham’s 
calculation. The samples were measured in triplicate to 
ensure that the developed formulations having suitable 
viscosity to avoid the rapid pre-corneal elimination of  
drug.
Gelling capacity
The prepared formulations were evaluated for gelling 
capacity in order to ascertain the composition suitable 
for use as in situ gelling system. The gelling capacity was 
determined by placing 1 mL of  prepared formulation 
into a test tube contatining 5 mL of  STF pH 7.4 at 
37°C. The time taken to transition of  solution to gel 
and the time taken for the formed gel to dissolve were 
visually observed. The congo red dye was added into 
the formulation to give visualised appearance of  formed 
gel. The gelling capacity of  the formulations was graded 
in four groups such as no gelation (-), poor (+), good 
(++) and excellent (+++) based on the gelation time 
and time period for which the formed gel remains as 
such.21,22 
In-vitro drug release studies
In-vitro drug release studies were conducted using 
dialysis membrane method in triplicate.23 Firstly, the 
dialysis membrane (molecular weight cut-off  12000-
14000 Da) which was soaked overnight in the dissolution 
medium was opened as a bag and tied at one-end. About 
1 mL of  the selected formulation comprising a combi-
nation of  Carbopol®/HPMC was placed into one-end 
tied dialysis bag and then added 0.5 mL of  STF pH 7.4 
to simulate the gel formation in the eye after instilla-
tion of  in situ gel preparation. Thereafter, second-end 
of  dialysis bag was also tied properly and immersed in a 
beaker containing 100 mL of  STF pH 7.4 which simu-
lates the tear fluid and it’s pH. The beaker was placed in 
a shaker water bath which was set at 50 rpm and 37°C. 
About 2 mL of  the sample was withdrawn at 0.5, 1, 2, 
3, 4, 6 and 8 h and replaced the same amount of  freshly 
prepared STF to maintain the sink conditions. The 
samples were analyzed using UV-Visible spectropho-
tometer at 257 nm using STF as a blank. 
The resultant release data was fitted into different 
release kinetic models i.e. zero order, first order, Higuchi, 
Hixon-crowell and Korsemeyer-peppas in order to 
determine the drug release pattern and release mecha-
nism. The time taken to release 50% of  the drug (T50%) 
was calculated and treated statistically using one-way 
analysis of  variance (ANOVA). When there was a 
statistically significant difference, a post hoc Tukey’s 
HSD (honestly significant difference) test was performed. 
A value of  p<0.05 was considered as statistically 
significant.
Sterility testing
Ocular products has to be sterile, thus it is necessary 
to carry out sterility testing. The selected formulation 
was aseptically transferred into sterile fluid thioglycolate 
medium and incubated for not less than 14 days at 35°C 
Table 1: Composition of in situ gels containing sulfacetamide sodium.
Ingredients (% w/v) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Sulfacetamide sodium 10 10 10 10 10 10 10 10 10 10
Carbopol® 940 0.3 0.5 0.8 0.8 0.8 0.8 - - - -
Carbopol® 934 - - - - - - 0.6 0.8 0.8 0.8
HPMC E4M 0.6 0.6 0.6 1.0 1.5 2.0 1.0 1.0 1.5 2.0
Sodium chloride 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9
Methyl paraben 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Propyl paraben 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Water qs ad 100 100 100 100 100 100 100 100 100 100
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to evaluate the growth of  bacteria. The sterility of  the 
formulation was visually determined by the clarity of  
the medium until 14 days.24-27
Antimicrobial efficacy studies
The antimicrobial efficacy studies were carried out 
by disk diffusion technique to ascertain the biological 
activity of  the selected formulation. The conventional 
eye drops (Albucid®10%) served as a reference and 
selected formulation was placed into cups bored into 
sterile Muller Hinton Agar medium previously seeded 
with Staphylococcus aureus, Escherichia coli and klabsiella 
pneumoniae microorganisms. The plates were incubated 
for 24 h at 37°C and the zone of  inhibition was mea-
sured in mm. Each formulation was tested in triplicate. 
The results were treated statistically using Independent 
samples t-test. A value of  p<0.05 was considered as sta-
tistically significant.
RESULTS AND DISCUSSION
The obtained results of  appearnace and clarity, pH, 
drug content, viscosity and gelling capacity for prepared 
in situ gel formulations are shown in Table 2.
Appearance and clarity, pH and drug content
All the prepared formulations were found to be trans-
parent and clear excluding the formulations consisting 
of  0.8% w/v of  Carbopol® 940 (F6) and Carbopol® 
934 (F10) in combination with HPMC (2% w/v). These 
two formulations were found to be highly clear viscous 
solutions with no flow which might be due to high 
concentration of  both Carbopol® and HPMC. Hence, 
formulations were not prepared with further increase in 
the concentrations of  both polymers. The pH of  
formulations were found to be in the range of  5.97 to 6.71. 
The combination of  water soluble polymeric system i.e. 
Carbopol®/HPMC aided to reduce the acidity of  the 
solution. The pH of  formulation would raises instantly 
to pH 7.4 (an ideal ocular pH) after instillation into eye 
due to pH of  lacrimal secretion. Thus, the formulations 
were considered to be suitable for opthalmic adminis-
tration and may not cause any irritation to ocular tissues 
upon administration.2,28 The dug content of  all the 
formulations was found to be in the acceptable range 
of  98.63% to 99.63% and results demonstrated the 
uniform distribution of  drug in the prepared formulations.
Viscosity
Viscosity of  formulations is an important factor in 
determining residence time of  drug in the eye as the 
low viscosity solutions may drain faster after insitillation 
into eye and high viscosity solutions would be difficult 
for instillation and also have poor spreadability in the eye.
Viscosity of  all the formulations was found to be in 
the range of  64.8 to 1857 cP. The viscosity was directly 
dependent on the polymeric content of  the formulations 
and increase in the polymer concentration caused to 
increase in viscosity of  the formulations. Formulations 
consisting of  Carbopol® 940 showed higher viscosity 
compared to Carbopol® 934. It might be due to differ-
ences in their crosslinking density as Carbopol® 940 has 
high crosslinking density and Carbopol® 934 has low 
Table 2: Results of physicochemical characterization of in situ gel formulations.
Formulation Clarity pH Drug content (%) Viscosity (cP)
Gelling 
capacity*
F1 Transparent and Clear 6.71 99.13 ± 0.35 64.80 ± 0.71 -
F2 Transparent and Clear 6.27 99.07 ± 0.51 86.05 ± 0.64 +
F3 Transparent and Clear 5.97 99.27 ± 0.15 259.20 ± 7.07 ++
F4 Transparent and Clear 6.03 98.63 ± 0.23 1023.00 ± 63.64 ++
F5 Transparent and Clear 6.02 98.67 ± 0.21 1209.00 ± 28.28 +++
F6 Clear and Viscous 6.27 98.87 ± 0.32 1857.00 ± 82.02 NS**
F7 Transparent and Clear 6.20 99.63 ± 0.15 685.10 ±12.59 +
F8 Transparent and Clear 6.19 98.90 ± 0.20 726.50 ± 0.00 ++
F9 Transparent and Clear 6.08 99.00 ± 0.40 1063.75 ± 7.14 ++
F10 Clear and Viscous 6.19 98.80 ± 0.20 1572.50 ± 68.59 NS**
*“-” no gelation, “+” gelation immediate but dissolves rapidly (1-2 h), “++” gelation immediate and remain for few h (3-4 h), “+++” 
stiff gel is formed immediately and remain for extended period (more than 6-8 h).
**Not Studied for gelling capacity.
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crosslinking density.9,29 Remarkable increase in the 
viscosity of  formulations from 64.8 to 259.2 cP with the 
increase in the concentration of  Carbopol® 940 from 
0.3 to 0.8 %w/v. The same phenomena was observed 
with the formulations consisiting of  Carbopol®/HPMC 
polymeric mixture i.e. increase in the concentration of  
HPMC E4M from 0.6 to 2 % w/v (F3 to F6) while 
maintaining the Carbopol® 940 concentration constant 
at 0.8 %w/v. The similar findings was observed with 
Carbopol® 934 (0.6-0.8 %w/v) and HPMC E4M 
(1-2 %w/v) in formulations F7 to F10. The results are 
well in correlation with the Nanjwade et al.5 and Pandey 
et al.30 where the researchers used a combination of  
Carbopol® 934/HPMC E4M and Carbopol® 940/
HPMC E4M at various concentrations to formulate pH 
trggered in situ gels containing ketorolac tromethamine 
and levobunolol hydrochloride, respectively.
Formulations, F1 to F5 and F7 to F9 were found to be 
free flowing in nature. However, formulations F6 and 
F10 were not pourable in nature as they exhibited higher 
viscosity due to higher content of  polymeric system. 
Hence, these two formulations were not considered for 
further studies.
Gelling capacity
An optimal in situ gelling formulation should have the 
balanced gelling capacity and viscosity which enables 
easy administration to the eyes with good gel formation 
by undergoing rapid sol to gel transition upon contact at 
the affected site. Besides, enhancing the residence time 
of  drug at pre-corneal surface dependent on the viscosity 
of  the formulations.31
Formulation F1 containing 0.3 %w/v Carbopol® 940 
and 0.6 %w/v HPMC E4M was assigned with ‘-’ sign 
as it is not having gelling ability at the pH of  STF (pH 
7.4) due to the low viscosity of  solution and hence were 
abandoned for further studies. With increase in the 
concentration of  Carbopol® and HPMC, the formula-
tions retained their liquid state at room temperature and 
at the formulated pH and increased the gelling capacity 
of  the formulations upon exposure to pH of  STF due 
to increase in the viscosity of  formulations. Among all, 
formulation F5 demonstrated excellent gelling capacity 
and assigned with ‘+++’ sign. They formed stiff  gel 
immediately and remained for extended period of  time 
(more than 6-8 h). 
The formation of  stiffer gel might be due to hydrophobic 
nature of  Carbopol® backbone and with increasing in 
the concentration, large amount of  polymeric chains 
develop hydrophobic interchain aggregation. Also, due 
to increased ionization of  functional groups present 
in Carbopol® as a result of  increasing pH, leading to 
an increased replusion of  negative charges along the 
polymer backbone and the subsequent expansion of  
polymeric network. Furthermore, by increasing the 
concentration of  Carbopol®/HPMC in the aqueous 
environment, they form a stable three dimensional 
viscoelastic network.32,33 The formulation of  such 
in situ gels facilitates the sustained drug release locally 
by preserving their integrity without dissolving and 
eroding for prolonged period of  time.
In-vitro drug release studies
The results of  in-vitro drug release study was shown in 
Figure 1. The reference product released about 99.27% 
of  drug within 2 h. However, the selected formulations 
F3, F4 and F5 released 90% of  drug within 4, 6 and 
8 h, respectively. These three formulations had same 
concentration of  Carbopol® 940 (0.8% w/v) but the 
concentration of  HPMC E4M as a viscosity enhancer 
increased from 0.6 to 1.5 %w/v. Similarly, the formula-
tion F8 and F9 released 90% of  drug within 3 and 4 h, 
respectively. The formulation F8 and F9 contained same 
amount of  Carbopol® 934 (0.8 %w/v) but the concen-
tration of  HPMC E4M increased from 1 to 1.5 %w/v. 
Therefore, the in vitro drug release results demon-
strated that higher viscosity with stronger gelling ablility 
plays an important role in sustaining the drug release 
from the formulations for prolonged period of  time.
The T50% of  reference formulation (Albucid
®10%), F3, 
F4, F5, F8 and F9 were 0.28, 0.48, 0.93, 2.86, 0.56 and 
0.76 h, respectively. As the formulation F3 had an ini-
tial burst release at an initial hour, no statistically signifi-
cant difference was observed between reference and F3. 
However, a statistically significant difference was observed 
Figure 1: In-vitro release profile of sulfacetamide sodium 
from Reference (Albucid®10%), Carbopol®940/HPMC in situ 
gels (F3: 0.8/0.6%w/v, F4: 0.8/1.0%w/v, F5: 0.8/1.5%w/v) and 
Carbopol®934/HPMC in situ gels (F8: 0.8/1.0%w/v, F9: 0.8/1.5 
%w/v).
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between reference, F4 and F5 as the initial burst release 
was decreased and exhibited sustained drug release with 
an increasing the concentration of  HPMC E4M. The 
formulation F5 (2.86 h) had better sustained release 
profile compared to other in situ gel formulations and 
marketed eye drops. It could be due to the higher vis-
cosity and excellent gelling capacity of  the formulation 
which supported to immediate transition of  solution to 
gel at ocular pH and remained in the gel form for a 
prologned period of  time to sustain the sulfacetamide 
sodium release for 8 h. This phenomenon eliminates the 
aforementioned disadvantages of  eye drops i.e. rapid 
precorneal elimination of  formulation caused by blink-
ing of  eyes and tear secretion and freqeuncy of  dosing 
frequency of  currently available sulfacetamide sodium 
eye drops (every 2-3 h). Therefore, the in situ gel for-
mulation acheives the improved patient compinace and 
conveince with the dosing administration of  every 8 
h. Formulation F5 was selected as the best among the 
prepared formulations and evaluated for sterility testing 
and antimicrobial efficacy studies.
In order to find out the kinetic of  drug release, the 
in-vitro drug release data was fitted into different 
release kinetic models. The best fit model of  release 
pattern was considered with highest regression value 
(r2) of  zero and first order. The regression values of  
Higuchi model which indicate diffusion mechanism and 
Hixon-crowell model which indicate erosion mechanism 
were compared to identify the release mechanism. 
The release mechanism can be further confirmed by 
the release exponent (n) value in Korsemeyer-peppas 
model. The release kinetic results of  in situ gels are 
presented in Table 3. The formulation F5 and conven-
tional eye drops showed identical kinetic of  drug release 
which was followed zero order release pattern and 
non-fickian diffusion (combination of  diffusion and 
erosion) mechanism (n value was in between 0.43-0.85). 
Sterility testing
The results of  the sterility test on the formulation F5 
(Carbopol® 940/HPMC-0.8/1.5 %w/v) is shown in 
Figure 2. The results indicated that there is no evidence 
of  microbial growth on the fluid thioglycolate medium 
during the incubation period of  14 days at 35°C. Therefore, 
the formulation was found to be clear without 
appearance of  turbidity which confirmed the steriltiy of  
formulation.
Antimicrobial efficacy studies
The zone of  inhibition results from antimicrobial efficacy 
studies are shown in Table 4 and depicted in Figure 3. 
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Pundir and Jain34 when the diameter of  zone of  inhibition 
is more than 18 mm, it is considered that formulations 
have very active antimicrobial activity. Thus, it indicated 
that sulfacetamide sodium retained its very active anti-
microbial efficiency even after being formulated in an 
in situ gelling system. 
CONCLUSION
Sulfacetamide sodium was successfully formulated 
as pH dependent in situ ocular gel using Carbopol®/
HPMC as a polymeric system. All the formulations were 
clear and free flowing solutions other than F6 and F10. 
The formulation F5 was found to be sterile and showed 
excellent gelling capacity. It also demonstrated a good 
viscosity and sustained the drug release over a period of  
8 h. The antimicrobial efficacy of  selected formulation 
was similar to commercial eyes drops (Albucid®10%). 
Therefore, it was concluded that in situ gelling formula-
tion with Carbopol®/HPMC would invariably improve 
the patient’s compliance by minimising the frequency of  
drug administration and could be a viable alternative to 
the conventional commercial product.
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SUMMARY
In-situ gels has received extensive attention over the 
past few years as they are capable of  undergoing rapid 
solution-to-gel transformation due to physico-chemi-
cal changes occurring in the eye. Hence the developed 
sulfaceacetamide sodium in situ gel formulation is a 
better alternate to exisiting conventional eye drops by 
virtue of  improved precoreneal residence time of  dosage 
form at the site of  administration, sustained action, 
better therapeutic efficiency and consequently reduces 
the dosing frequency with improved patient compli-
ance and convenience. 
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